Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Cytek Biosciences, Inc.NASDAQ: CTKB

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 2.3% from a year ago

Net receivables stood at $56.48M at the end of Q1 FY2026, up 2.3% from a year earlier and down 21.7% from the prior quarter. Over 3 fiscal years it compounded at +12.3% a year.

Context

  • Net receivables amounted to 12.6% of total assets at the end of Q1 FY2026, up 1.1 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +2.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$56.48M-21.7% QoQ
Last fiscal yearDec 2025
$72.13M+19.0% YoY
Year agoMar 2025
$55.21M+2.3% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%——
1 year+19.0%——
3-year CAGR+12.3%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
72.13M USD
Year-over-year change
+19.0%
4-year CAGR
+24.9%

Net Receivables vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's Mar 2026 net receivables of $56.48M is the 5th highest of the 6 companies compared; the peer median is $441.8M.
  • Its year-over-year change of +2.3% is the 3rd highest of 6, against a peer median of -6.0%.
  • Net receivables amounts to 12.6% of total assets for CTKB, versus a peer median of 5.5%.
CTKB Competitors Peer median
Net Receivables for CTKB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AAgilent Technologies, Inc.Jul 2026$1.48B +6.9%+1.9%10.6%
BRKRBruker CorporationJun 2026$875.4M +18.5%+7.3%14.5%
BIOBio-Rad Laboratories, Inc.Jun 2026$441.8M -6.0%-1.5%4.3%
TXG10x Genomics, Inc.Sep 2026$58.76M -39.2%-7.5%5.5%
CTKBCytek Biosciences, Inc.Mar 2026$56.48M +2.3%+12.3%12.6%
LABStandard BioTools Inc.Mar 2026$16.64M -53.1%-8.1%2.6%
Peer median (excluding CTKB) $441.8M-6.0%-1.5%5.5%

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents364.62M296.6M167.3M98.72M90.85M
Short-term Investments044.55M95.11M179.15M170.68M
Net Receivables29.63M50.88M56.12M60.59M72.13M
Inventory32.17M48.15M60.88M43.89M48.43M
Other Current Assets708K6.7M2.56M1.97M2.98M
Total Current Assets431.73M454.02M392.06M396.45M392M
Property, Plant & Equipment (Net)5.85M27.57M29.26M28.13M29.32M
Goodwill10.14M10.14M16.18M16.66M16.7M
Intangible Assets4.74M4.33M23.08M20.13M16.82M
Long-term Investments001.6M1.6M0
Tax Assets9.17M20.46M30.49M33.37M0
Other Non-current Assets1.67M2.96M1.79M3.16M6.7M
Total Non-current Assets31.57M65.46M102.4M103.05M69.55M
Total Assets463.31M519.48M494.46M499.5M461.54M
Account Payables3.03M4.81M3.03M5.53M6.41M
Short-term Debt0580K565K4.66M6.3M
Tax Payables3.88M1.67M1.3M3.56M0
Deferred Revenue8.1M14.54M24.13M26.61M29.57M
Other Current Liabilities12.04M17.3M16.71M1.86M18.14M
Total Current Liabilities33.18M49.04M56.23M67.66M77.8M
Long-term Debt02.27M1.65M1.05M525K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)9.79M13.12M15.13M16.1M18.34M
Other Non-current Liabilities14.95M17.18M18.91M11.4M9.09M
Total Non-current Liabilities24.74M44.89M45.17M36.1M42M
Total Liabilities57.92M93.93M101.39M103.76M119.8M
Common Stock126K135K131K129K129K
Retained Earnings(19.61M)(17.03M)(29.18M)(35.2M)(101.74M)
Accumulated OCI897K(697K)(1.28M)16K2.24M
Other Stockholders Equity00000
Minority Interest343K251K000
Total Equity405.39M425.55M393.06M395.74M341.74M
Total Debt018.09M14.14M17.02M23.74M
Net Debt(364.62M)(278.51M)(153.16M)(81.7M)(67.11M)

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.